Illumina, Inc. has signed a commercial, multi-year, genotyping services agreement with GlaxoSmithKline (GSK).

Under the terms of the agreement, Illumina will use Sentrix Arrays in conjunction with the company's GoldenGate and Infinium assays to conduct genetic studies for thousands of samples provided by GSK. The blanket agreement enables multiple projects to be conducted over period of time.

Illumina has worked directly with GSK since June 2001, genotyping samples for a number of pharmacogenomics studies. The Company is providing no further detail.

Illumina develops and markets next-generation tools for the large-scale analysis of genetic variation and function.